IL146012A0 - Method of enhancing the efficacy of anti-tumor agents - Google Patents

Method of enhancing the efficacy of anti-tumor agents

Info

Publication number
IL146012A0
IL146012A0 IL14601200A IL14601200A IL146012A0 IL 146012 A0 IL146012 A0 IL 146012A0 IL 14601200 A IL14601200 A IL 14601200A IL 14601200 A IL14601200 A IL 14601200A IL 146012 A0 IL146012 A0 IL 146012A0
Authority
IL
Israel
Prior art keywords
efficacy
enhancing
tumor agents
tumor
agents
Prior art date
Application number
IL14601200A
Other languages
English (en)
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of IL146012A0 publication Critical patent/IL146012A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
IL14601200A 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents IL146012A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (1)

Publication Number Publication Date
IL146012A0 true IL146012A0 (en) 2002-07-25

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14601200A IL146012A0 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Country Status (18)

Country Link
US (3) US6171620B1 (enExample)
EP (1) EP1212068A4 (enExample)
JP (1) JP2002542296A (enExample)
KR (1) KR100693796B1 (enExample)
CN (1) CN1188137C (enExample)
AU (1) AU781301B2 (enExample)
BG (1) BG64940B1 (enExample)
BR (1) BR0010082A (enExample)
CA (1) CA2368618C (enExample)
HU (1) HUP0200840A3 (enExample)
IL (1) IL146012A0 (enExample)
MX (1) MXPA01010899A (enExample)
NO (1) NO20015227L (enExample)
NZ (1) NZ514521A (enExample)
PL (1) PL350918A1 (enExample)
RU (1) RU2271829C2 (enExample)
WO (1) WO2000064455A1 (enExample)
ZA (1) ZA200108012B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
IL152428A0 (en) 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
CA2368618A1 (en) 2000-11-02
US6171620B1 (en) 2001-01-09
HUP0200840A3 (en) 2003-04-28
US6620779B2 (en) 2003-09-16
US20010000730A1 (en) 2001-05-03
CN1352561A (zh) 2002-06-05
CN1188137C (zh) 2005-02-09
PL350918A1 (en) 2003-02-10
RU2271829C2 (ru) 2006-03-20
KR100693796B1 (ko) 2007-03-12
MXPA01010899A (es) 2003-06-24
AU4486300A (en) 2000-11-10
CA2368618C (en) 2011-03-01
AU781301B2 (en) 2005-05-12
NO20015227L (no) 2001-12-27
BR0010082A (pt) 2002-01-15
KR20020000557A (ko) 2002-01-05
HUP0200840A2 (hu) 2002-07-29
NZ514521A (en) 2003-07-25
BG106057A (en) 2002-04-30
BG64940B1 (bg) 2006-10-31
NO20015227D0 (no) 2001-10-25
EP1212068A4 (en) 2007-03-14
US6426094B2 (en) 2002-07-30
JP2002542296A (ja) 2002-12-10
ZA200108012B (en) 2003-03-26
US20020198153A1 (en) 2002-12-26
EP1212068A1 (en) 2002-06-12
WO2000064455A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
IL146012A0 (en) Method of enhancing the efficacy of anti-tumor agents
GB9903830D0 (en) Process-systems integration method
GB9911863D0 (en) Therapeutic agents
IL145798A0 (en) Fap-activated anti-tumor compounds
GB9905010D0 (en) Therapeutic agents
GB9904786D0 (en) Therapeutic agents
GB9907243D0 (en) Therapy
GB9930570D0 (en) Therapy
GB9911881D0 (en) Therapeutic agents
GB9903476D0 (en) Therapeutic agents
GB9926161D0 (en) Methods
GB9905817D0 (en) Methods
GB9903119D0 (en) Therapeutic agents
GB9902881D0 (en) Therapeutic agents
GB2350378B (en) Headstones
GB9908525D0 (en) Methods
GB9914943D0 (en) Methods
GB0206401D0 (en) Side effects treatment
GB9923740D0 (en) Surface treatment
TW387252U (en) Massager
GB9924712D0 (en) Therapeutic method
GB9919258D0 (en) Methods
GB9923144D0 (en) Methods
GB9921756D0 (en) Methods
GB9919676D0 (en) Methods